Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 3362

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 3362
---
 promise. The unifying theme in our portfolio is to address significant unmet medical needs by commercializing
    innovative therapeutic products, if approved.

    ●
    Providing
    attractive economic upside to our partners at research universities and medical centers. We have a structure wherein Ocean Biomedical
    houses each of its programs in a subsidiary. We believe this structure is optimal to provide attractive economic incentives to the
    discovering institution and its researchers. Our subsidiary structure is intended to enable us to offer equity in future programs
    to the licensing institution and the researchers who discover our product candidates. We believe this structure will make us a partner
    of choice for both institutions and researchers and aligns our interests with theirs toward the goal of maximum returns.

    ●
    Employing
    a multi-disciplinary approach to drug discovery and development across our programs. Our business model is based on bringing together
    the appropriate disciplines and expertise needed for each of our programs and leveraging learnings across programs and disease areas.
    Common ties between many diseases are becoming apparent and similar therapeutic strategies are increasingly being applied to different
    diseases. For example, our oncology and fibrosis programs are both based upon chitinase biology. Another example is the confluence
    of thinking about immunology and oncology therapeutic approaches which led to the advent of immune checkpoint inhibitors.

    ●
    Exploiting
    multiple commercialization options to maximize each program’s value. Throughout the development of our product candidates,
    we continually assess that program’s potential paths to market, and we will endeavor to maximize commercial value through various
    options, including internal advancement, partnerships with established companies, and spin-outs or IPOs. We believe that our structure
    and operational strategy enables us to assess and pursue the course that maximizes outcomes for patients and value for our shareholders.

    ●
    Leadership
    team comprised of academic, scientific and business innovators. We have assembled an industry-leading, multi-disciplinary team consisting
    of physicians, scientists and business leaders with significant experience in progressing product candidates from early-stage research
    through clinical trials, regulatory approval and ultimately to commercialization.

12

We
believe our differentiated business model enables us to advance the commercialization of our products, if approved, and will allow us
to replicate our licensing partnerships through aligned incentive structures with research universities and medical centers.

Feeding
our Pipeline: Harnessing Innovations from Research Centers

Our
innovative business model is aimed at translating biomedical inventions from research universities